ArticlePharmacology research & perspectives2026
Investigating the Phytochemical Constituents, Anti-Inflammatory, and Neuropharmacological Activities of Podocarpus neriifolius Leaves Through FT-IR, GC-MS, Experimental Studies, Molecular Docking, and Molecular Dynamics Simulations.
Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Podocarpus neriifolius, a widely distributed medicinal plant in South and Southeast Asia, has traditionally been used to treat rheumatism and joint pain. This study aimed to investigate the phytochemical profile and therapeutic potential of the ethanolic leaf extract of P. neriifolius (EEPN) using integrated in vitro, in vivo, and in silico approaches. Phytochemical analysis via FT-IR and GC-MS revealed the presence of steroidal glycosides, flavonoids, alkenes, aliphatic compounds, steroids, saponins, and other glycosides. In a COX inhibition assay, EEPN demonstrated notable in vitro anti-inflammatory effects, further validated in a mouse paw edema test. In Swiss albino mice, EEPN (200 and 400 mg/kg) showed increased head dipping in HBT (43.4 ± 1.14 and 69.2 ± 1.22), where the standard showed (57.5 ± 1.01), and improved open-arm entries and time in EPM (260.3 and 280.6 s) compared to the standard (245.2 s). EEPN produced a dose-dependent sedative effect both in HCT and OFT. Furthermore, EEPN significantly lowered immobility time in the tail suspension and forced swimming tests, demonstrating its antidepressant effects. According to molecular docking studies, the phytochemicals in EEPN showed a strong affinity for binding to important drug target proteins linked to inflammation, anxiety, and depression. The EEPN had binding affinities of -6.6, -5.4, and -10 kcal/mol with COX2, GABA
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.